Pharmaceuticals
YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in eight participants, including ...
2024-12-21 16:23
2801
United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI
CHICAGO, Dec. 20, 2024 /PRNewswire/ -- As RSNA 2024 concluded, United Imaging Intelligence (UII), a subsidiary of United Imaging Group specializing in medical AI, made a significant impression with a visionary showcase that seamlessly aligned with the event's theme: "Building Intelligent Connecti...
2024-12-20 22:00
1079
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr.Lilly Xu as its new Chief Technology Officer (CTO). With over30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and ...
2024-12-20 21:30
963
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-12-20 20:20
3367
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
* Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY * Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY * Gross margin increased to 82.6% from 80.9% in the same period of FY2024 * Total operating expenses decreased to RMB 276.4 million, down 31.6%...
2024-12-19 22:05
1818
BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development
CHENGDU, China, Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin Zhanchang, Chairman of the Board of Directors of BGM Group and Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the sales team to visit their long-term strategic partner, Jointow...
2024-12-19 21:30
1357
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South,Belgium, facilita...
2024-12-19 17:02
1506
LG Corp. Chairman and CEO Kwang Mo Koo sends 2025 New Year Address to 270,000 global employees on December 19
* "Let's Shape LG's Future with the DNA of Challenge and Change We've had Since Day 1" * Highlighting LG's Spirit – the DNA of challenge and change since Day 1 - "LG's Day 1 spirit of choosing what others wouldn't dare comes from our DNA of challenge and change as we serve our customer...
2024-12-19 13:00
1116
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS")China on December 16th. The partnership was officially formalized with the signing of a colla...
2024-12-19 12:40
952
Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid bi...
2024-12-19 01:00
1767
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...
2024-12-18 22:03
1312
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
* In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous(SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), show...
2024-12-18 21:43
2006
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct ...
2024-12-18 19:34
2224
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic develop...
2024-12-18 13:09
1591
U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) * STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio a...
2024-12-18 11:50
850
Fosun International Awarded TVB's Highest Honor "Outstanding ESG Award"
HONG KONG, Dec. 18, 2024 /PRNewswire/ -- On 13 December 2024, the "TVB ESG Awards" ceremony, hosted by Television Broadcasts Limited (hereinafter referred to as "TVB"), was held at the Hong Kong Convention and Exhibition Centre. Fosun International was honored with the highest accolade, the "Outs...
2024-12-18 11:43
1527
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: * IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 * The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies,...
2024-12-18 10:59
1580
Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSI...
2024-12-18 08:00
1369
Complete Genomics Adds Eurofins Clinical Enterprise, LLC to its Sequencing Service Provider Program
FRAMINGHAM, Mass., Dec. 17, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, California based genomics tools manufacturer, today announced Framingham, Massachusetts based Eurofins Clinical Enterprise, LLC as the newest addition to its Sequencing Service Provider Program. Complete Genomics'...
2024-12-17 22:00
786
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
Agreement to Deliver Critical Medicines ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on theAsia-Pacific market is pleased to announce that Hupan Phar...
2024-12-17 21:30
1392
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 305 media titles]
2024-12-20 16:25
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 305 media titles]
2024-12-19 17:56
ADA Acquires Customore, Launching the Most Advanced Intelligent Commerce Solution for the CPG Industry
[Picked up by 296 media titles]
2024-12-17 11:00
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 296 media titles]
2024-12-20 18:11
Most Read
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
4884
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
4786